FDA Approves First mRNA Flu Vaccine, Clearing Moderna Shot for Older Adults

What Happens Next

• →Traditional flu vaccine manufacturers such as Sanofi, GSK, and CSL Seqirus accelerate internal mRNA R&D programs or pursue licensing deals to avoid losing share in the 50+ age segment where Moderna now competes directly.
• →Hospital systems and pharmacy chains serving older adults allocate a portion of their seasonal flu vaccine orders to mFlusiva, reducing unit volumes for incumbent egg-based and cell-based vaccine suppliers by an estimated 5-15% in the first season.
• →Regulatory agencies in Europe and Asia-Pacific receive accelerated mRNA flu vaccine submissions from Moderna and competitors, using the FDA approval as a precedent to streamline review timelines for mRNA-platform vaccines targeting respiratory pathogens beyond COVID-19.

Near-term: Moderna's revenue guidance for the next quarter is revised upward as pharmacy chains and health systems place initial mFlusiva orders ahead of flu season, lifting Moderna's share price 8-15% from pre-approval levels. Long-term: mRNA-based flu vaccines capture 20-30% of the U.S. seasonal influenza vaccine market, structurally reducing egg-based vaccine production capacity and shifting manufacturing investment toward lipid nanoparticle supply chains.